Explore the words cloud of the MeningoSpeed project. It provides you a very rough idea of what is the project "MeningoSpeed" about.
The following table provides information about the project.
|Coordinator Country||France [FR]|
|Total cost||71˙429 €|
|EC max contribution||50˙000 € (70%)|
1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
|Duration (year-month-day)||from 2019-03-01 to 2019-06-30|
Take a look of project's partnership.
Meningococcal disease (MD), caused by Neisseria meningitidis serogroups (mainly ABCXWY), annually affects 1.2 million people worldwide (mainly children and young). Due to its high lethality (8-15% treated patients), permanent sequelae and epidemic potential, MD represents a major public health problem. Despite the societal burden, there is a lack of rapid and accurate diagnostic tools for timely and early treatment that results very costly for healthcare systems (e.g. direct costs valued in € 68 m/hospital/year). In response to the unmet need, BioSpeedia (spin-off from the Institute Pasteur, France) has vast experience in infectious diseases management and is developing the first-ever gold nanoparticle-based immunochromatographic test with demonstrated diagnostic capability for the six Nm serogroups. MeningoSpeed is a non-invasive, accurate (sensitivity and specificity >93%), rapid (<15 min vs PCR: 3h) and cost-competitive in vitro diagnostic test (€45 sample, at least 25 % cheaper than latex agglutination tests and PCR alternatives) for MD diagnosis. Our one-step solution will result on added value for patients, physicians and healthcare purchasers by improving disease monitoring in an accurate and timely fashion way, reducing deaths and sequelae. MeningoSpeed will provide healthcare systems with limited resources with a reliable and cost-effective diagnostic tool, leading to significant cost-savings. MeningoSpeed´s high accuracy and performance under a faster and cheaper cost make it a disruptive solution with great potential for commercial success in the growing point-of-care market (€33 B by 2022, CAGR 10%). Thus, MeningoSpeed is projected to be a profitable business opportunity and a core source of growth for the company (ca. €33 M of accumulated net profit during 2022-2026). A next feasibility study covering the technological, commercial and financial issues will enable us to finalize our business plan and secure our steps towards the successful market launch.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MENINGOSPEED" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "MENINGOSPEED" are provided by the European Opendata Portal: CORDIS opendata.
First in the world ecological and sustainable cream for wound care, based on microalgaprasinococcus capsulatusRead More
Mobile technology that brings personalized audio into your lifeRead More
NATURE FRIENDLY WATER HYDRAULIC STEERING SYSTEMRead More